Swiss pharma giant Roche (ROG: SIX) has been awarded a Breakthrough Therapy badge for a combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) against hepatocellular carcinoma (HCC) in the first-line setting.
HCC is the most common form of liver cancer. Roche has been trialling a combination of its checkpoint inhibitor, Tecentriq, with its anti-VEGF biologic, Avastin, in a Phase Ib trial, results from which were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June.
Those results showed that after a median follow-up of 10.3 months, responses were seen in 15 of 23 “efficacy-evaluable” patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze